التفاصيل البيبلوغرافية
| العنوان: |
Pharmacological Wnt ligand inhibition overcomes key tumor-mediated resistance pathways to anti-PD-1 immunotherapy. |
| المؤلفون: |
DeVito, Nicholas C., Sturdivant, Michael, Thievanthiran, Balamayooran, Xiao, Christine, Plebanek, Michael P., Salama, April K.S., Beasley, Georgia M., Holtzhausen, Alisha, Novotny-Diermayr, Veronica, Strickler, John H., Hanks, Brent A. |
| المصدر: |
Cell Reports; May2021, Vol. 35 Issue 5, pN.PAG-N.PAG, 1p |
| مستخلص: |
While immune checkpoint blockade is associated with prolonged responses in multiple cancers, most patients still do not benefit from this therapeutic strategy. The Wnt-β-catenin pathway is associated with diminished T cell infiltration; however, activating mutations are rare, implicating a role for autocrine/paracrine Wnt ligand-driven signaling in immune evasion. In this study, we show that proximal mediators of the Wnt signaling pathway are associated with anti-PD-1 resistance, and pharmacologic inhibition of Wnt ligand signaling supports anti-PD-1 efficacy by reversing dendritic cell tolerization and the recruitment of granulocytic myeloid-derived suppressor cells in autochthonous tumor models. We further demonstrate that the inhibition of Wnt signaling promotes the development of a tumor microenvironment that is more conducive to favorable responses to checkpoint blockade in cancer patients. These findings support a rationale for Wnt ligand-focused treatment approaches in future immunotherapy clinical trials and suggest a strategy for selecting those tumors more responsive to Wnt inhibition. [Display omitted] • Proximal Wnt ligand signaling activity is associated with anti-PD-1 resistance • Wnt signaling drives kynurenine production and PMN-MDSC accumulation in tumors • Wnt ligand inhibition enhances the efficacy of PD-1 blockade in transgenic models • Wnt inhibition creates a more favorable immune microenvironment in cancer patients Anti-PD-1-refractory melanoma exhibits elevated Wnt ligand signaling activity. DeVito et al. demonstrate that pharmacologic inhibition of proximal Wnt ligand signaling sensitizes transgenic models of melanoma and lung cancer to anti-PD-1 checkpoint inhibitor immunotherapy by reversing dendritic cell tolerization and suppressing recruitment of granulocytic myeloid-derived suppressor cells to the tumor bed. [ABSTRACT FROM AUTHOR] |
|
Copyright of Cell Reports is the property of Elsevier B.V. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
